[go: up one dir, main page]

MX2020006170A - Composiciones y metodos para prevenir y tratar afecciones. - Google Patents

Composiciones y metodos para prevenir y tratar afecciones.

Info

Publication number
MX2020006170A
MX2020006170A MX2020006170A MX2020006170A MX2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A MX 2020006170 A MX2020006170 A MX 2020006170A
Authority
MX
Mexico
Prior art keywords
compositions
methods
preventing
treating conditions
treating
Prior art date
Application number
MX2020006170A
Other languages
English (en)
Inventor
Jason M Criscione
Original Assignee
Ansella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansella Therapeutics Inc filed Critical Ansella Therapeutics Inc
Publication of MX2020006170A publication Critical patent/MX2020006170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Sealing Material Composition (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

En el presente documento se proporcionan composiciones que comprenden una emulsión estable de agua en silicona, y métodos y kits que comprenden las composiciones para tratar afecciones.
MX2020006170A 2017-12-18 2018-12-14 Composiciones y metodos para prevenir y tratar afecciones. MX2020006170A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607286P 2017-12-18 2017-12-18
US201762609127P 2017-12-21 2017-12-21
PCT/US2018/065710 WO2019125945A1 (en) 2017-12-18 2018-12-14 Compositions and methods for preventing and treating conditions

Publications (1)

Publication Number Publication Date
MX2020006170A true MX2020006170A (es) 2020-11-24

Family

ID=66815467

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006170A MX2020006170A (es) 2017-12-18 2018-12-14 Composiciones y metodos para prevenir y tratar afecciones.
MX2023008764A MX2023008764A (es) 2017-12-18 2020-07-13 Composiciones y metodos para prevenir y tratar afecciones.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008764A MX2023008764A (es) 2017-12-18 2020-07-13 Composiciones y metodos para prevenir y tratar afecciones.

Country Status (8)

Country Link
US (3) US10668046B2 (es)
EP (1) EP3727382A4 (es)
JP (2) JP6945083B2 (es)
CN (2) CN121422237A (es)
BR (1) BR112020012195A2 (es)
CA (1) CA3086082A1 (es)
MX (2) MX2020006170A (es)
WO (1) WO2019125945A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020012195A2 (pt) * 2017-12-18 2020-11-24 Ansella Therapeutics, Inc. composições e métodos para prevenir e tratar condições
WO2022047042A1 (en) * 2020-08-26 2022-03-03 Oticara, Inc. Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation
US12286451B2 (en) 2020-11-23 2025-04-29 Medtech Products Inc. Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU47604A1 (es) 1964-12-17 1966-06-17
US4847071A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
NZ227994A (en) 1988-02-16 1990-09-26 Richardson Vicks Inc Skin conditioning composition comprising glycerin and a silicone fluid phase
US5256422A (en) 1991-03-28 1993-10-26 Micro Vesicular Systems, Inc. Lipid vesicle containing water-in-oil emulsions
FR2686510A1 (fr) 1992-01-27 1993-07-30 Oreal Emulsion eau-dans-huile stable au cours du temps a haute teneur en silicone.
WO1993019723A1 (en) 1992-03-31 1993-10-14 Alberto-Culver Company Emulsifier compositions for applying silicone oil to hair
US5304334A (en) 1992-04-28 1994-04-19 Estee Lauder, Inc. Method of preparing a multiphase composition
DE69734498T2 (de) 1996-05-20 2006-08-10 Shiseido Co. Ltd. Oel-in-wasser emulsion und oel-in-wasser emulgator
DE69614578T2 (de) * 1996-12-18 2002-06-13 The Procter & Gamble Company, Cincinnati Stabiles make-up mit hohem sonnenschutzfaktor
US6537537B2 (en) 1997-06-12 2003-03-25 The Procter & Gamble Company Water-in-silicone emulsion cosmetic compositions
US6121373A (en) 1998-10-07 2000-09-19 Dow Corning Corporation Method of making thick water-in-silicone emulsions
US6570054B1 (en) * 1999-05-21 2003-05-27 The Procter & Gamble Company Absorbent article having a stable skin care composition
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US20020022040A1 (en) * 2000-07-10 2002-02-21 The Proctor & Gamble Company Methods of enhancing delivery of oil-soluble skin care actives
EP1313427A2 (en) * 2000-07-10 2003-05-28 The Procter & Gamble Company Methods of enhancing delivery of oil-soluble skin care actives
JP2003104826A (ja) * 2001-09-28 2003-04-09 Kanebo Ltd Ｗ／ｏ／ｗ型複合エマルジョン
US7010494B2 (en) * 2003-03-27 2006-03-07 University Of Washington Performing predictive pricing based on historical data
DE10326899A1 (de) * 2003-06-14 2004-12-30 Beiersdorf Ag Kosmetische Zubereitungen mit stabilisierten Konservierungsmitteln
MXPA06004826A (es) * 2003-10-31 2006-07-03 Procter & Gamble Composicion para el cuidado de la piel que contiene acido deshidroacetico y activos para el cuidado de la piel.
WO2005048929A2 (en) * 2003-11-13 2005-06-02 Galileo Pharmaceuticals, Inc. Plant-derived protein extract compositions and methods
JP4589050B2 (ja) 2003-12-22 2010-12-01 日本精化株式会社 ジエステル及び油剤、並びに化粧料及び皮膚外用剤
US20050222169A1 (en) 2004-01-16 2005-10-06 Nawaz Ahmad Compositions and methods of treating infections
WO2006004759A2 (en) * 2004-06-29 2006-01-12 Mcclellan Stephanie N Topical compositions for anti-aging
DE102005020583B4 (de) * 2004-09-06 2016-02-18 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Zubereitung, insbesondere kosmetische Zubereitung sowie ihre Verwendung
EP1681046A3 (de) * 2004-11-13 2008-07-30 Clariant Produkte (Deutschland) GmbH Kosmetische, pharmazeutische und dermatologische Zubereitungen enthaltend Copolymerwachse
JP2008535973A (ja) 2005-04-07 2008-09-04 ダウ・コーニング・コーポレイション エラストマーを含有するシリコーン中水型エマルジョン
US20080193428A1 (en) 2005-04-27 2008-08-14 Shenzhen Phlora Biotechnology Limited Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity
ITMI20060122A1 (it) 2006-01-25 2007-07-26 Polichem Sa Composizioni per uso vaginale
WO2007088417A1 (en) 2006-02-03 2007-08-09 Wockhardt Limited Silicone oil-in-water emulsions-formulation, production and use
HUE034298T2 (en) 2007-05-17 2018-02-28 Helperby Therapeutics Ltd Use of 4- (Pyrrolidin-1-yl) quinoline derivatives to kill clinically latent microorganisms
US20090035236A1 (en) 2007-07-31 2009-02-05 Maes Daniel H Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent
WO2009135135A2 (en) * 2008-05-01 2009-11-05 Chia Soo Fibromodulin formulation for reducing corneal scarring
ES2336995B1 (es) * 2008-10-13 2011-02-09 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
GB0822823D0 (en) 2008-12-15 2009-01-21 Dow Corning Silicone oi-in-water emulsions
JP5940556B2 (ja) 2010-12-28 2016-06-29 ユニリーバー・ナームローゼ・ベンノートシヤープ エマルジョンの製造方法
ITRM20130199A1 (it) * 2013-04-03 2014-10-04 Irbm Science Park S P A Peptidi per uso dermatologico e/o cosmetico
BR112020012195A2 (pt) 2017-12-18 2020-11-24 Ansella Therapeutics, Inc. composições e métodos para prevenir e tratar condições

Also Published As

Publication number Publication date
CN111655262A (zh) 2020-09-11
US10668046B2 (en) 2020-06-02
WO2019125945A1 (en) 2019-06-27
EP3727382A4 (en) 2021-09-08
US20250345308A1 (en) 2025-11-13
US20190183854A1 (en) 2019-06-20
EP3727382A1 (en) 2020-10-28
CN121422237A (zh) 2026-01-30
JP6945083B2 (ja) 2021-10-13
US12201607B2 (en) 2025-01-21
US20200360340A1 (en) 2020-11-19
CA3086082A1 (en) 2019-06-27
JP2021191791A (ja) 2021-12-16
JP7502242B2 (ja) 2024-06-18
BR112020012195A2 (pt) 2020-11-24
JP2021506956A (ja) 2021-02-22
MX2023008764A (es) 2023-08-02

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2020009455A (es) Composiciones que comprenden cepas bacterianas.
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX379270B (es) Composiciones que comprenden cepas bacterianas.
BR112018004620A2 (pt) moduladores da expressão de kras
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
CR20170005A (es) Derivados de insoindolina
CR20190471A (es) Moduladores de la expresión de pcsk9
MX2021003170A (es) Moduladores de la expresion de pnpla3.
CL2018003028A1 (es) Loci genéticos asociados con una mayor fertilidad en el maíz (divisional de la solicitud n° 2071-2016).
UY36221A (es) Derivados de isoindolinona
MX389499B (es) Metodos, composiciones y usos relacionados con los mismos
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
MX2023008764A (es) Composiciones y metodos para prevenir y tratar afecciones.
CL2017000151A1 (es) Derivados de piridona
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CL2021001246A1 (es) Moduladores de expresión irf5.
MX380530B (es) Combinación de herbicida.